Ghoshal Kaushik 4

4 · RESMED INC · Filed Mar 11, 2025

Form 4

Period: 2025-03-10

Chief Commercial Officer, SaaS

Transactions

Exercise/Conversion
ResMed Common Stock Options
2025-03-10−5,882→ 0 total
Exercise: $211.76From: 2020-11-19Exp: 2027-11-19→ ResMed Common Stock (5,882 underlying)
Exercise/Conversion
ResMed Common Stock
2025-03-10$211.76/sh+105$22,235→ 9,999 total
Sale
ResMed Common Stock
2025-03-10$239.31/sh−9,745$2,332,096→ 9,725 total
Exercise/Conversion
ResMed Common Stock Options
2025-03-10−105→ 0 total
Exercise: $211.76From: 2020-11-19Exp: 2027-11-19→ ResMed Common Stock (105 underlying)
Exercise/Conversion
ResMed Common Stock Options
2025-03-10−3,589→ 0 total
Exercise: $146.34From: 2019-11-21Exp: 2026-11-21→ ResMed Common Stock (3,589 underlying)
Exercise/Conversion
ResMed Common Stock
2025-03-10$211.76/sh+5,882$1,245,572→ 19,470 total
Exercise/Conversion
ResMed Common Stock
2025-03-10$146.34/sh+169$24,731→ 9,894 total
Exercise/Conversion
ResMed Common Stock
2025-03-10$146.34/sh+3,589$525,214→ 13,588 total
Exercise/Conversion
ResMed Common Stock Options
2025-03-10−169→ 0 total
Exercise: $146.34From: 2019-11-21Exp: 2026-11-21→ ResMed Common Stock (169 underlying)

Holdings

Footnotes (3)

[F1]The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024.
[F2]This transaction was executed in multiple trades at prices ranging from $236.62 - $242.73. The price reported above reflects the weighted average sale price.
[F3]Represents date options first become exercisable. Options vest 1/3 per year.

Documents

1 file